Publications by Medical Specialty - Endocrinology, Diabetes & Metabolism
These publications were authored or co-authored by Quest Diagnostics staff.
- Adult Medicine
- Clinical and Lab healthcare professionals
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Family medicine practitioners
- General Health and Wellness
- Geriatrics/Age Management
- Health Information Technology
- Infectious Disease
- Internal Medicine
- Nurse practitioners
- Pathology, Anatomic
- Pathology, Laboratory Medicine
- Physician assistants
- Prescription Drug Monitoring
- Primary Care
- Sports Medicine
- Toxicology/Pain Management
- Women's Health/OB/GYN
Knowledge of an inflammatory biomarker of cardiovascular risk leads to biomarker-based decreased risk in pre-diabetic and diabetic patients.
Authors: Alcivar-Franco D, Purvis S, Penn MS, Klemes A
J Int Med Res. 2020 Jan;48(1):300060517749111. doi: 10.1177/0300060517749111.
Disclaimer: One or more of the authors of this publication were employed at the time by Cleveland HeartLab, a subsidiary of Quest Diagnostics.
Outreach and Connection to Care for Chronic Kidney Disease in a Workplace Wellness Setting: A Cost-Effectiveness Analysis.
Authors: Li Y, Devlin JJ.
Popul Health Manag. 2020 Jan 2. doi: 10.1089/pop.2019.0206. [Epub ahead of print].
Authors: Yasun E, Trusty T, Abolhosn RW, Clarke NJ, Mezić I.
Sci Rep. 2019 Dec 27;9(1):19885.
Free thyroxine concentrations in sera of individuals with Familial Dysalbuminemic Hyperthyroxinemia: a comparison of three methods of measurement.
Authors: Refetoff S, Scherberg N, Yuan C, Wu W, Wu Z, McPhaul MJ.
Thyroid. 2019 Dec 10. doi: 10.1089/thy.2019.0058. [Epub ahead of print]
Authors: El-Khoury JM, Remaley AT, Nordestgaard BG, Kaufman HW, Mora S, Cao J, Meeusen JW.
Clin Chem. 2019 Dec;65(12):1487-1492.
Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment.
Authors: Luttmann-Gibson H, Mora S, Camargo CA, Cook NR, Demler OV, Ghoshal A, Wohlgemuth J, Kulkarni K, Larsen J, Prentice J, Cobble M, Bubes V, Li C, Friedenberg G, Lee IM, Buring JE, Manson JE.
Contemp Clin Trials. 2019 Dec;87:105854.
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
Authors: Bril F, McPhaul MJ, Caulfield MP, Clark VC, Soldevilla-Pico C, Firpi-Morell RJ, Lai J, Shiffman D, Rowland CM, Cusi K.
Diabetes Care 2019 Oct 11. doi: 10.2337/dc19-1071. [Epub ahead of print]
Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia.
Authors: Puangpetch A, Srisawasdi P, Unaharassamee W, Jiratjintana N, Vanavanan S, Punprasit S, Na Nakorn C, Sukasem C, Kroll MH
Pharmgenomics Pers Med. 2019 Aug 6;12:155-166.
Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis.
Authors: Wong RJ, Tran T, Kaufman H, Niles J, Gish R.
PLoS One. 2019 Aug 1;14(8):e0220612.
Authors: Krainev AA, Mathavan VK, Klink DF, Saxe JM, Ong GKB, Murphy JK.
J Surg Case Rep. 2019 Jun 28;2019(6):rjz196.
Disclaimer: One or more of the authors of this publication were employed at the time by AmeriPath, a subsidiary of Quest Diagnostics.